Zoetis

5 Giralda Farms
Madison
New Jersey
07940
United States

Tel: 973660-7491

Show jobs for this employer

170 articles with Zoetis

  • Nov. 12, 2020 13:00 UTC Zoetis Receives European Commission Marketing Authorization for Librela ® (bedinvetmab) The first injectable monoclonal antibody authorized for alleviation of osteoarthritis pain in dogs Librela works differently from other pain medications, combining one month of pain control and increased mobility, with a proven safety and efficacy profile Librela has a unique mode of action, inhibiting Nerve Growth Factor—a key player in osteoarthritis

  • Reports Revenue of $1.8 Billion, Growing 13%, and Net Income of $479 Million, or $1.00 per Diluted Share, Both Increasing 11% on a Reported Basis, for Third Quarter 2020 Reports Adjusted Net Income of $524 Million, or Adjusted Diluted EPS of $1.10 for Third Quarter 2020 Delivers 15% Operational Growth in Revenue and 20% Operational Growth in Adjusted Net Income for Third Quarter 2020

  • The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a fourth quarter 2020 dividend payable to holders of the company’s common stock of $0.20 per share. The dividend is to be paid on Tuesday, Dec. 1, 2020, to holders of record on Wednesday, Oct. 21, 2020. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65

  • Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 5, 2020. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Glenn David will review third quarter 2020 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website

  • Zoetis Inc. (NYSE:ZTS) will participate in the 18th Annual Morgan Stanley Healthcare Conference on Wednesday, Sept. 16, 2020. Kristin Peck, Chief Executive Officer, and Glenn David, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. They are scheduled to present virtually at 8:00 a.m. ET. Investors and other interested parties will be able to

  • Reports Flat Revenue of $1.5 Billion, and Net Income of $377 Million, or $0.79 per Diluted Share, Increasing 2% and 3%, Respectively, on a Reported Basis for Second Quarter 2020 Reports Adjusted Net Income of $427 Million, or Adjusted Diluted EPS of $0.89 for Second Quarter 2020 Delivers 4% Operational Growth in Revenue and 4% Operational Growth in Adjusted Net Income for Second Quarter 2020 Raises and Narrows Full Year 2020 Reven

  • Trianni, Inc. and Zoetis announced a collaboration for the development of transgenic monoclonal antibody platforms for the discovery of new veterinary treatments.

  • Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Aug. 6, 2020. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Glenn David will review second quarter 2020 financial results and respond to questions from financial analysts during the call.

  • Zoetis Inc. (NYSE:ZTS) will participate in the William Blair 40th Annual Growth Stock Conference on Thursday, June 11, 2020. Glenn David, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 12:20 p.m. ET (11:20 a.m. CT). Investors and other interested parties will be able to access a live audio webcast of the present

  • Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2020 Virtual Jaws & Paws Conference on Wednesday, May 27, 2020. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 12:40 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/

  • Zoetis Inc. announced that it has agreed to sell $1.25 billion of senior notes, consisting of $750 million aggregate principal amount of 2.000% senior notes due 2030 and $500 million aggregate principal amount of 3.000% senior notes due 2050, in an underwritten public offering.

  • Simparica Trio marks the first all-in-one protection in the U.S. against heartworm disease, ticks* and fleas, roundworms and hookworms** in a single monthly chewable

  • Feb. 21, 2020 13:30 UTC PARSIPPANY, N.J.--( BUSINESS WIRE )-- Zoetis Inc. (NYSE:ZTS) will participate in the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020, in Boston, Mass. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 2:10 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http:/

  • Zoetis Inc. (NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2019 and provided full year guidance for 2020.

  • The Board of Directors of Zoetis Inc. has declared a second quarter 2020 dividend payable to holders of the company’s common stock of $0.20 per share.

  • Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Merrill Lynch Animal Health Summit on Monday, Feb. 24, 2020, in New York, N.Y. Glenn David, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 8:40 a.m. ET.

  • Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Feb. 13, 2020. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Glenn David will review fourth quarter and full year 2019 financial results and respond to questions from financial analysts during the call.

  • Zoetis Inc. (NYSE:ZTS) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2020, in San Francisco, Calif. Kristin Peck, who will become Chief Executive Officer of Zoetis on January 1, 2020, will represent the company and respond to questions from analysts.

  • The dividend is to be paid on Tuesday, March 3, 2020, to holders of record on Friday, January 17, 2020.

  • Zoetis Inc. announced the acquisition of ZNLabs, a full-service veterinary clinical reference laboratory company with a network of labs across the U.S.